Sehl P, Tom J Y, Oare D, Lowe D G
Department of Cardiovascular Research, Genentech Inc., South San Francisco, CA 94080, USA.
Mol Cell Biochem. 1998 Jan;178(1-2):317-24. doi: 10.1023/a:1006823732336.
Systemic clearance of atrial natriuretic peptide (ANP) is in part due to neutral endopeptidase (NEP) proteolysis and natriuretic peptide receptor-C (NPR-C) mediated endocytosis. Biological responses to ANP are primarily mediated by the membrane guanylyl cyclase-A/natriuretic peptide receptor-A (NPR-A). Analogs of ANP selective for NPR-A and/or resistant to NEP may have increased activity in those tissues where NPR-C and NEP are coexpressed with NPR-A. The analog of ANP termed vANP; [(R3D, G9T, R11S, M12L, G16R)ANP] is selective for human NPR-A with at least 10,000 fold reduction in affinity for human NPR-C. We report that rat NPR-A is insensitive to 10 nM vANP, demonstrating the limitations of this species in evaluating human therapeutic candidates. As an alternative approach we tested the binding and potency of receptor-selective and NEP-resistant ANP analogs in rhesus monkey tissues. Competition binding studies with a simplified version of vANP, sANP [(G9T, R11S, G16R)rANP], in rhesus monkey kidney and lung membrane preparations shows displacement of 125I-ANP from only a fraction of the total ANP receptor population, 30 and 85%, respectively. The remaining ANP binding sites can be occupied with the NPR-C selective ligand cANP(4-23). These data strongly suggest that only two classes of ANP receptor are present in these membrane preparations, NPR-A and NPR-C. The NEP resistant sANP derivative called sANP(TAPR) was 8 fold more potent (ED50 = 0.6 nM) than rANP (ED50 = 5 nM) in stimulating cGMP production in the lung membrane preparation. Our results demonstrate that the rhesus monkey natriuretic peptide receptors reflect the pharmacology of the human receptors, and that this species may be suitable to determine the role of NPR-C and NEP in peptide clearance and attenuating functional responses.
心房利钠肽(ANP)的全身清除部分归因于中性内肽酶(NEP)的蛋白水解作用以及利钠肽受体-C(NPR-C)介导的内吞作用。对ANP的生物学反应主要由膜鸟苷酸环化酶-A/利钠肽受体-A(NPR-A)介导。对NPR-A具有选择性和/或对NEP有抗性的ANP类似物,在NPR-C和NEP与NPR-A共表达的组织中可能具有增强的活性。被称为vANP的ANP类似物;[(R3D,G9T,R11S,M12L,G16R)ANP]对人NPR-A具有选择性,对人NPR-C的亲和力降低了至少10000倍。我们报告大鼠NPR-A对10 nM的vANP不敏感,这表明该物种在评估人类治疗候选药物方面存在局限性。作为一种替代方法,我们测试了受体选择性和NEP抗性的ANP类似物在恒河猴组织中的结合和效力。用简化版的vANP,即sANP [(G9T,R11S,G16R)rANP]对恒河猴肾和肺膜制剂进行竞争结合研究,结果显示仅从总ANP受体群体的一部分中置换出125I-ANP,分别为30%和85%。其余的ANP结合位点可用NPR-C选择性配体cANP(4-23)占据。这些数据强烈表明,在这些膜制剂中仅存在两类ANP受体,即NPR-A和NPR-C。在肺膜制剂中,被称为sANP(TAPR)的NEP抗性sANP衍生物在刺激cGMP产生方面比rANP(ED50 = 5 nM)强8倍(ED50 = 0.6 nM)。我们的结果表明,恒河猴利钠肽受体反映了人类受体的药理学特性,并且该物种可能适合用于确定NPR-C和NEP在肽清除和减弱功能反应中的作用。